Investigation on the Frequency and Severity of Common Adverse Reactions of Japanese Encephalitis Vaccines.
- Author:
Boo Young KIM
1
;
Dong Hyun KIM
;
Hun Jae LEE
;
Soo Kyung JUNG
;
Xiao Shan LI
;
Un Yeong GO
;
Sook Kyung PARK
;
Young Jin HONG
Author Information
1. Department of Pediatrics, College of Medicine, Inha University, Korea. hongyjin@inha.ac.kr
- Publication Type:Original Article
- Keywords:
Japanese encephalitis;
Vaccine;
Adverse effects
- MeSH:
Asian Continental Ancestry Group;
Child;
Cohort Studies;
Cooperative Behavior;
Encephalitis, Japanese;
Fever;
Humans;
Immunization;
Japanese Encephalitis Vaccines;
Korea;
Prospective Studies;
Public Health;
Telephone;
Vaccination;
Vaccines;
Vaccines, Attenuated;
Vaccines, Inactivated
- From:Korean Journal of Pediatric Infectious Diseases
2009;16(2):183-190
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the number and severity of adverse reactions after Japanese Encephalitis (JE) vaccination in children using different vaccines (inactivated vaccine or live attenuated vaccine) and to determine the ability and safety of the vaccines to provide effective immunization for JE. METHODS: From August 2006 to February 2007, we conducted a prospective cohort study of the adverse reactions associated with JE immunization in Korea. We investigated common adverse reactions during the 4 days following immunization using telephone collaborations with four public health centers and nine pediatric clinics. RESULTS: The mean age of children receiving the inactivated vaccines and live attenuated vaccines, respectively, were 1.4 y (range: 1 to 8.5) and 1.7 y (range: 1 to 8.3). The number of children that received the inactivated vaccines was 425 (64.6%). A total of 233 (35.4%) received the live attenuated vaccines. Fourteen children (3.3%) had more than one localized adverse event with the inactivated vaccine, and six (2.6%) had more than one event with the live attenuated vaccine (P=0.607). Systemic adverse reactions occurred in 5.2% vs. 8.2%, respectively, of these groups (P=0.131). Fever was more common in the live attenuated vaccine group than in the inactivated vaccine group on the day of vaccination (P=0.026). CONCLUSIONS: The rate of adverse events in our study was even lower than that previously reported. No significant difference in outcomes between inactivated vaccine and live attenuated vaccine was found in JE-immunized children. Fever was more common in the live attenuated vaccine group than in the inactivated vaccine group on the day of vaccination.
